As a projects associate of our Life Sciences Group, Lisa-Cathrin Uebel focuses on regulatory pharmaceutical and medical devices law as well as commercial related issues. Lisa advises national and international clients on contractual matters, particularly concerning development, manufacturing and supply contracts for pharmaceuticals, as well as distribution and services agreements. Her main focus lies in the pharmaceutical industry.
Lisa further advises and accompanies pharmaceutical companies on implementing compliance policies and the respective codices of the industry. Prior to becoming a member of Hogan Lovells, Lisa worked as a freelance consultant for a law firm and concentrated on the sector of pharmaceutical law. Therefore, she has experience in contract drafting and negotiations on a national and international level. Lisa studied law at Rheinische Friedrich-Wilhelms-University in Bonn.
In addition, Lisa successfully completed a supplementary qualification program in pharmaceutical law at Philipps-University in Marburg and a postgraduate Master’s program (LL.M.) in medical law at the Heinrich-Heine-University in Duesseldorf. During her legal traineeship at the Frankfurt Court of Appeals she worked, inter alia, for the legal department of an international pharmaceutical company and the Association of Statutory Health Insurance Physicians.
Drafting agreements regarding the regulatory compliance of a UK based pharmaceutical company.
In-depth analysis of the new EU and German legislation concerning Digital Health.
Working on several clinical trial agreements for a Swiss based international pharma company.
Development of general rules and guidelines for a pharmaceutical company to comply with the special requirements and codices of the pharma industry.
Advisory on the distributing structure for a pharmaceutical product in several EU countries.
Drafting, modifying and assessing terms and conditions for various agreements in the pharma industry.
Advising an international pharmaceutical company on its obligation to publish clinical trial data.